Chandra Bhushan Prasad

Chandra Bhushan Prasad

Auto-generated profile, based on publicly available information

Chandra Bhushan Prasad

The Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center and College of Medicine, Columbus, OH, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
SPShyam Babu Prasad
Shyam Babu Prasad
SYSuresh Singh Yadav
Suresh Singh Yadav
LPLaxmi Kant Pandey
Laxmi Kant Pandey
SSSunita Singh
Sunita Singh
GNGopeshwar Narayan
Gopeshwar Narayan
PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers. The role of PARP1 in cervical cancer (CC) resistance and implication of PARP inhibitor is yet to be elucidated. Our data demonstrates significantly higher expression of PARP1 in primary cervical tumors and CC cell lines SiHa and ME180. Upon cisplatin treatment CC cells display significant overexpression of PARP1 and its hyperactivation. PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. PARP inhibited cells show delay in resolution of γH2A.X foci and prolonged late S and G2-M phase arrest resulting in apoptosis. Further, PARP inhibition disrupts the localization of base excision repair (BER) effector XRCC1 and non-homologous end joining (NHEJ) proteins Ku80 and XRCC4. Due to disrupted relocation of repair factors, cisplatin induced stalled replication forks collapse and convert into double strand breaks (DSBs). Interestingly, PARP inhibition also shows anti-migratory and anti-invasive properties in CC cells, increases anchorage independent cell death and induces anoikis. Collectively, our data demonstrates therapeutic potential of PARP inhibitor in cervical cancer.

11 July 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
MVMahalingam Rajamanickam Vijayakumar
Mahalingam Rajamanickam Vijayakumar
RKRamoji Kosuru
Ramoji Kosuru
SSSanjay Kumar Singh
Sanjay Kumar Singh
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
GNGopeshwar Narayan
Gopeshwar Narayan
SSSanjay Singh
Sanjay Singh
trans-Resveratrol (RSV) is a natural molecule proved for cancer preventive and therapeutic activities without any potential side effects. In recent years, RSV is also proved for its cytotoxic potential against glioma. However, practical application of RSV in glioma chemotherapy is limited because of its low systemic circulation time and short biological half-life resulting from rapid metabolism and accelerated elimination from the blood pool. Therefore, the main objective of this study was to enhance systemic circulation time and short biological half-life of RSV using poly(D,L-lactide-co-glycolide)–D-α-tocopheryl polyethylene glycol 1000 succinate blend nanoparticles (RSV-PLGA-BNPs). RSV-PLGA-BNPs were successfully formulated and optimized by a single-emulsion solvent-evaporation technique. RSV-PLGA-BNPs were evaluated by various state of the art techniques for extensive nanoparticulate characterization. Cytotoxicity against C6 cells, cellular internalization and haemocompatibility were studied for proving anticancer potential and safety of RSV-PLGA-BNPs. Pharmacokinetic and tissue distribution studies were carried out in Charles Foster rats after intravenous (i.v) administration. RSV-PLGA-BNPs showed significantly higher cytotoxicity and excellent cell internalization in C6 glioma cells. Haemocompatibility studies suggested that RSV-PLGA-BNPs are safe for i.v administration. Pharmacokinetic studies showed prolonged systemic circulation of RSV-PLGA-BNPs up to 36 h with approximately 18.11 times higher plasma half-life than RSV solution. Tissue distribution studies showed higher brain accumulation of RSV-PLGA-BNPs than RSV. Therefore, RSV-PLGA-BNPs can be applied as a potential tool for enhancing systemic circulation and plasma half-life with superior anticancer efficacy against glioma.

19 January 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZHZhipeng Hong
Zhipeng Hong
TLTao Liu
Tao Liu
LWLingfeng Wan
Lingfeng Wan
PFPengyan Fa
Pengyan Fa
Pankaj KumarPankaj Kumar
Pankaj Kumar
JZJunran Zhang
Junran Zhang
Over 50% of all patients with cancer are treated with radiotherapy. However, radiotherapy is often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene epoxidase (SQLE) controls cholesterol biosynthesis by converting squalene to 2,3-oxidosqualene. Given that SQLE is frequently overexpressed in human cancer, this study investigated the importance of SQLE in breast cancer and non–small cell lung cancer (NSCLC), two cancers often treated with radiotherapy. SQLE-positive IHC staining was observed in 68% of breast cancer and 56% of NSCLC specimens versus 15% and 25% in normal breast and lung tissue, respectively. Importantly, SQLE expression was an independent predictor of poor prognosis, and pharmacologic inhibition of SQLE enhanced breast and lung cancer cell radiosensitivity. In addition, SQLE inhibition enhanced sensitivity to PARP inhibition. Inhibition of SQLE interrupted homologous recombination by suppressing ataxia-telangiectasia mutated (ATM) activity via the translational upregulation of wild-type p53-induced phosphatase (WIP1), regardless of the p53 status. SQLE inhibition and subsequent squalene accumulation promoted this upregulation by triggering the endoplasmic reticulum (ER) stress response. Collectively, these results identify a novel tumor-specific radiosensitizer by revealing unrecognized cross-talk between squalene metabolites, ER stress, and the DNA damage response. Although SQLE inhibitors have been used as antifungal agents in the clinic, they have not yet been used as antitumor agents. Repurposing existing SQLE-inhibiting drugs may provide new cancer treatments. Significance: Squalene epoxidase inhibitors are novel tumor-specific radiosensitizers that promote ER stress and suppress homologous recombination, providing a new potential therapeutic approach to enhance radiotherapy efficacy.

10 June 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZQZhaojun Qiu
Zhaojun Qiu
PFPengyan Fa
Pengyan Fa
TLTao Liu
Tao Liu
CPChandra B. Prasad
Chandra B. Prasad
SMShanhuai Ma
Shanhuai Ma
JZJunran Zhang
Junran Zhang
There is currently a lack of precise predictive biomarkers for patient selection in clinical trials of inhibitors targeting replication stress (RS) response proteins ATR and CHK1. The objective of this study was to identify novel predictive biomarkers for the response to these agents in treating non–small cell lung cancer (NSCLC). A genome-wide loss-of-function screen revealed that tumor suppressor PPP2R2A, a B regulatory subunit of protein phosphatase 2 (PP2A), determines sensitivity to CHK1 inhibition. A synthetic lethal interaction between PPP2R2A deficiency and ATR or CHK1 inhibition was observed in NSCLC in vitro and in vivo and was independent of p53 status. ATR and CHK1 inhibition resulted in significantly increased levels of RS and altered replication dynamics, particularly in PPP2R2A-deficient NSCLC cells. Mechanistically, PPP2R2A negatively regulated translation of oncogene c-Myc protein. c-Myc activity was required for PPP2R2A deficiency-induced alterations of replication initiation/RS and sensitivity to ATR/CHK1 inhibitors. We conclude that PPP2R2A deficiency elevates RS by upregulating c-Myc activity, rendering cells reliant on the ATR/CHK1 axis for survival. Our studies show a novel synthetic lethal interaction and identify PPP2R2A as a potential new predictive biomarker for patient stratification in the clinical use of ATR and CHK1 inhibitors.Significance: This study reveals new approaches to specifically target PPP2R2A-deficient lung cancer cells and provides a novel biomarker that will significantly improve treatment outcome with ATR and CHK1 inhibitors.

1 July 2015 in Life Sciences
Verified
Journal Article
Closed access
SYSuresh Singh Yadav
Suresh Singh Yadav
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
SPShyam Babu Prasad
Shyam Babu Prasad
LPLakshmi Kant Pandey
Lakshmi Kant Pandey
SSSunita Singh
Sunita Singh
GNGopeshwar Narayan
Gopeshwar Narayan

31 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPChandra Bhushan Prasad
Chandra Bhushan Prasad
AOAdrian Oo
Adrian Oo
YLYujie Liu
Yujie Liu
ZQZhaojun Qiu
Zhaojun Qiu
YZYaogang Zhong
Yaogang Zhong
JZJunran Zhang
Junran Zhang
Checkpoint kinase 1 (CHK1) is critical for cell survival under replication stress (RS). CHK1 inhibitors (CHK1i’s) in combination with chemotherapy have shown promising results in preclinical studies but have displayed minimal efficacy with substantial toxicity in clinical trials. To explore combinatorial strategies that can overcome these limitations, we perform an unbiased high-throughput screen in a non-small cell lung cancer (NSCLC) cell line and identify thioredoxin1 (Trx1), a major component of the mammalian antioxidant-system, as a determinant of CHK1i sensitivity. We establish a role for redox recycling of RRM1, the larger subunit of ribonucleotide reductase (RNR), and a depletion of the deoxynucleotide pool in this Trx1-mediated CHK1i sensitivity. Further, the TrxR inhibitor auranofin, an approved anti-rheumatoid arthritis drug, shows a synergistic interaction with CHK1i via interruption of the deoxynucleotide pool. Together, we show a pharmacological combination to treat NSCLC that relies on a redox regulatory link between the Trx system and mammalian RNR activity.